How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-fingolimod.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo matching fingolimod — Competitive Intelligence Brief

Placebo matching fingolimod (Placebo matching fingolimod) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine-1-phosphate receptor modulator. Area: Immunology.

phase 3 Sphingosine-1-phosphate receptor modulator S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching fingolimod (Placebo matching fingolimod) — Biogen. Fingolimod is a sphingosine-1-phosphate receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing their infiltration into the central nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo matching fingolimod TARGET	Placebo matching fingolimod	Biogen	phase 3	Sphingosine-1-phosphate receptor modulator	S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
fingolimob (FTY)	fingolimob (FTY)	University Hospital, Clermont-Ferrand	marketed	Sphingosine-1-phosphate receptor modulator	S1P1 receptor (sphingosine-1-phosphate receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine-1-phosphate receptor modulator class)

Biogen · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching fingolimod — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-fingolimod. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab